Form 4 Filing for Allogene Therapeutics, Inc.

This Form 4 filing details transactions by Zachary Roberts, President and CEO of Allogene Therapeutics, Inc. On July 1, 2026, Roberts acquired 134,530 Restricted Stock Units (RSUs) with a post-transaction share count of 134,530. These RSUs vest in four equal annual installments starting July 20, 2026. Additionally, he acquired 476,190 stock options to purchase Common Stock, with 25% vesting on July 1, 2027, and the remainder vesting monthly thereafter. The exercise price for these options is $2.11 per share. All transactions were marked as direct ownership and acquired.